Eric Berger
Partner,
Eric
専門分野
Eric Berger is a member of Bain’s Healthcare & Life Sciences and Private Equity practices with more than 10 years of consulting experience.
Eric advises clients across a range of industries, with a focus in private equity funds as well as healthcare payers and services and biotech / pharma. He has additional experience in industrial goods and services and consumer packaged goods.
He holds expertise in topics related to commercial due diligence, business unit strategy, operating model, organization design, pricing, brand strategy and mergers & acquisitions.
Prior to joining Bain in 2011, Eric worked for a small consulting firm in Boston focused on the pharmaceutical, biotech and medical device industries. Previously, he was a researcher in organic chemistry at Harvard University. Eric has published in Science and the Journal of the American Chemical Society and was awarded a grant from the Howard Hughes Medical Institute and the Jean Dreyfus Boissevain scholarship.
Eric earned an MBA from MIT Sloan School of Management. He holds a BA cum laude and MA in chemistry from Harvard University.
Recent Insights
- “40% of pharma executives are baking expected savings from Generative AI into 2024 budgets ,” Press release, 2024年2月12日
- “How to Successfully Scale Generative AI in Pharma,” 論説, 2024年2月12日
- “Generative AI Will Transform Healthcare,” Global Healthcare Private Equity Report, 2024年1月3日, レポート
- “Inside Bain’s 2023 Healthcare Provider IT Report,” Webinar, 2023年9月20日
- “2023 Healthcare Provider IT Report: Doubling Down on Innovation,” 論説, 2023年9月12日